Low bone mineral density (BMD) and osteoporosis are prevalent in HIV-infected patients and were associated with HIV infection and tenofovir-containing ART.

Bianco, C., Rossetti, B., Gagliardini, R., Lamonica, S., Fanti, L., Lombardi, F., et al. (2014). Bone mineral density improvement after 48 weeks of switch to maraviroc+darunavir/ritonavir 300/800/100 mg QD, preliminary results of GUSTA study. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 17(4 Suppl 3), 19816-19816.

Bone mineral density improvement after 48 weeks of switch to maraviroc+darunavir/ritonavir 300/800/100 mg QD, preliminary results of GUSTA study

DE LUCA, ANDREA
2014-01-01

Abstract

Low bone mineral density (BMD) and osteoporosis are prevalent in HIV-infected patients and were associated with HIV infection and tenofovir-containing ART.
2014
Bianco, C., Rossetti, B., Gagliardini, R., Lamonica, S., Fanti, L., Lombardi, F., et al. (2014). Bone mineral density improvement after 48 weeks of switch to maraviroc+darunavir/ritonavir 300/800/100 mg QD, preliminary results of GUSTA study. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 17(4 Suppl 3), 19816-19816.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11365/1011879
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo